Notably, the interaction between CLEC14A and multimerin-2 (MMRN2) has been shown to facilitate angiogenic processes, and pharmacological disruption of this interaction significantly suppresses sprouting angiogenesis and impedes tumor growth, underscoring its potential as a therapeutic target in anti-angiogenic strategies. Here, CLEC14A is linked to neoplasm.